Documents

MOR/0.2R

96042335

Pricing and availability is not currently available.

biological source

human lung

growth mode

Semi-adherent aggregates

karyotype

Not specified

morphology

Not specified

products

Not specified

receptors

Not specified

application(s)

cell culture | mammalian: suitable

relevant disease(s)

cancer

shipped in

dry ice

storage temp.

−196°C

Related Categories

Cell Line Origin

Human lung adenocarcinoma, drug-resistant

Cell Line Description

The drug resistant cell line MOR/0.2R has been derived from the parent line, MOR, by continuous exposure to increasing concentrations of doxorubicin (also known as adriamycin). MOR/0.2R accumulate lower levels of doxorubicin than the parent line and have been shown to overexpress multi drug resistance associated protein (MRP). Expression of a 190kDa membrane protein associated with the degree of drug-resistance has been indicated. Cells grow as easily detaching aggregates.

Application

Analysis of acquired drug resistance, MRP studies

Culture Medium

RPMI 1640 + 2mM Glutamine + 0.2μg/ml Doxorubicin + 10% Foetal Bovine Serum (FBS).

Subculture Routine

Split subconfluent cultures (70-80%) 1:2 to 1:4 seeding at 2-4 x 10,000 cells/cm2 using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C. It is recommended to culture the cells without drug after resuscitation until the first passage. These cells produce a

Other Notes

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

RIDADR

NONH for all modes of transport

Certificate of Analysis
Certificate of Origin

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.